Last week’s headlines were dominated by acquisitions across the global dietary supplement universe, with P&G agreeing to acquire Thorne, Kirin snapping up Jamieson Wellness, and Lallemand announcing a deal for BIO-CAT Enzymes & Microbials.
P&G to acquire Thorne for US$3.8 billion
American multinational Procter & Gamble has agreed to acquire dietary supplement manufacturer Thorne from L Catterton’s Flagship Fund for $3.8 billion, strengthening its position in science-backed wellness and personalized health.
Thorne, which has experienced rapid growth and now generates over $500 million in annual revenue, has shifted its focus to younger consumers seeking performance-oriented, personalized health solutions.
The acquisition follows Thorne’s expansion under private equity ownership, marked by product innovation and a generational shift in the supplement market from boomers to millennials and Gen Z. The deal is expected to close later this year, pending regulatory approvals.
“For more than 40 years, Thorne has earned the trust of healthcare practitioners, consumers and partners by putting science, quality and the people we serve at the center of every decision,” said Colin Watts, chief executive officer of Thorne, in the company’s press release.
“As we looked to the future, we kept coming back to one question: What will best position Thorne to continue fulfilling its mission? We believe P&G is the right partner to help us expand our impact while staying true to the values and standards that have always defined Thorne,” he added.
Kirin acquires Jamieson Wellness for C$2.5 billion
Japan’s Kirin Holdings Company has agreed to acquire Jamieson Wellness Inc. for C$2.5 billion (US$1.78 billion), representing a significant step in expanding its Health Science business into North America.
The company states it is committed to becoming the most trusted health science company across Asia, Oceania, and North America.
Having acquired Australian supplement firm Blackmores in 2023 and Japanese cosmetics and supplement company FANCL in 2024 to establish a strong foundation in Asia and Oceania, Kirin turned its attention to North America, the world’s largest vitamins and dietary supplements market.
Kirin believes Jamieson Wellness is an ideal strategic fit because it brings established brands, strong customer relationships, broad distribution networks, and end-to-end capabilities spanning R&D, manufacturing and sales. These strengths are said to complement Kirin’s expertise in fermentation, biotechnology and proprietary health ingredients.
“The acquisition of Jamieson Wellness marks an important step in advancing Kirin’s Health Science vision to become a global leader in preventative health,” added Alastair Symington, CEO & Managing Director of Blackmores Limited. “It brings trusted brands, strong capabilities in innovation, brand building, manufacturing and go-to-market execution, and a scalable platform in the important North American market. Together, Kirin, Blackmores, FANCL and Jamieson Wellness strengthen a global platform now connecting North America, Asia and Oceania.”
Lallemand boosts U.S. footprint and capacity with BIO-CAT acquisition
Canada’s Lallemand Inc. has completed the acquisition of Virginia-based BIO-CAT Enzymes & Microbials, effective July 31, 2026. Both companies are privately held, and terms have not been disclosed.
IO-CAT was founded in 1988 by Ed Schuler and his son, Chris and was one of the first wholesalers of dietary enzymes in the United States, and the forerunners in developing formulas for use in digestive preparations. Today, BIO-CAT’s portfolio includes single-to multi-enzyme blends, probiotics, and unique microbial solutions.
By combining expertise in enzymes, microbial technologies, fermentation, and life sciences, the enlarged company is better positioned to accelerate innovation and deliver solutions that address evolving needs across human health, animal nutrition, agriculture, food, and industrial markets, according to a release from BIO-CAT.
“The acquisition will reinforce our presence in the dietary food supplement and health ingredient markets and increase our production footprint and capacity in the USA,” stated Antoine Chagnon, CEO of Lallemand. “This, in turn, should better enable us to meet the requirements of our existing and new customers across the global animal nutrition, agriculture and food industries.”
Lallemand currently operates over 45 yeast, bacteria, and fungi production sites across the world, including facilities in the U.S. The acquisition of BIO-CAT provides two additional sites located in the U.S.: Virginia and Minnesota.
